The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
CalvertAHNewellDRGumbrellLA. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-1756.
2.
SocinskiMSmitELoriganP. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naïve patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27(28):4787–4792.
3.
OkamotoHWatanabeKKunikaneH. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor -risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97(2):162–169.
4.
HeigenerDManegoldCJagerE. Multicenter randomised open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in “extensive disease” stage. Am J Clin Oncol. 2009;32(1):61–64.
5.
SchmittelASebastianMFischer von WeikersthalL. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011;22(8):1798–1804.
6.
SchmittelAvon WeikersthalLSebastianM. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2006;17(4):663–667.
7.
QuoixEBretonJDanielC. Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. Ann Oncol. 2001;12(7):957–962.
8.
OkamotoHWatanabeKNishiwakiY. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999;17(11):3540–3545.
9.
SkarlosDSamantasEBriassoulisE. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001;12(9):1231–1238.
10.
LariveSBombaronPRiouR. Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer. 2002;35(1):1–7.
11.
YilmazUPolatGAnarC. Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin. Indian J Cancer.2011;48(4):454–459.
12.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines –Small Cell Lung Cancer. V.2. 2013. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed January 14, 2013.
13.
CheungYWCradockJCVishnuvajjalaBRFloraKP. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987;44(1):124–130.
14.
HeskethPJKrisMGGrunbergSM. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103–109.
BaschEPrestrudAAHeskethPJ. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2011. J Clin Oncol. 2011;29(31):4189–4198.
RoilaFHerrstedtJAaproM. Guideline Update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia Consensus Conference. Ann Oncol.2010;21(suppl 5):232–243.
19.
GelingOEichlerHG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289–1294.
20.
CornelisonTLReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50(2):147–158.
21.
SmithTJKhatcheressianJLymanGH. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
CathomasRHarleAMeadGM. Glomerular filtration rate (GFR) in patients with stage I testicular seminoma treated with adjuvant carboplatin: a comparison of six formulae compared to a radioisotope gold standard. J Clin Oncol.2007;25(18 suppl):abstract 15504.
24.
BoumedienFArsenaultYLeTarteN.Impact of weight and creatinine measurements in carboplatin dosing. J Clin Oncol.2012;30(15 suppl):abstract e13027.
25.
EkhartCRodenhuisSSchellensJHMBeijnenJHHuitemaADR. Carboplatin dosing in overweight and obese patients with normal renal runction. Does weight matter?Cancer Chemother Pharmacol.2009;64(1):115–122.
26.
HerringtonJDTranHTRiggsMW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol.2006;57(2):241–247.
27.
KaagD.Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. Lung Cancer.2013;79(1):54–58.
28.
O'CearbhaillR.New guidelines for carboplatin dosing. Gyn Oncol Group Newsletter.2012;(Spring issue):5–6.
